Tell me about ADHD
Reading File
Finding Sources
Searching PubMed
"attention deficit hyperactivity disorder"[MeSH Terms] AND treatment
Searching the Web
ADHD attention deficit hyperactivity disorder overview diagnosis treatment 2025
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed
"attention deficit hyperactivity disorder"[MeSH Terms] AND diagnosis
I now have rich content across etiology, diagnosis, and treatment from authoritative textbooks. Let me compile a comprehensive answer.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Definition & Overview
ADHD is a heritable, chronic neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It is one of the most common psychiatric conditions of childhood, with 6–9% prevalence in children and adolescents worldwide, and persists into adulthood in roughly 50% of patients. Adult prevalence is approximately 3.1%, with the inattentive presentation being most common.
DSM-5 Diagnostic Criteria
To meet diagnosis, symptoms must:
- Be more frequent and severe than expected for developmental age
- Persist for ≥6 months
- Have onset before age 12
- Be evident in two or more settings (e.g., home and school)
- Cause functional impairment
Three subtypes:
| Subtype | Description |
|---|---|
| Combined | Meets criteria for both inattention and hyperactivity-impulsivity |
| Predominantly Inattentive | Difficulty sustaining attention, easily distracted, forgetful |
| Predominantly Hyperactive-Impulsive | Fidgeting, inability to stay seated, excessive talking, impulsive actions |
DSM-5 expanded criteria to more accurately characterize the disorder in adults, and a first-time adult diagnosis is compatible with both ICD-11 and DSM-5.
Etiology & Neurobiology
ADHD is a highly heritable neurobehavioral disorder. The core neurobiological model involves:
- Catecholamine dysregulation — aberrant dopamine (DA) and norepinephrine (NE) neurotransmission in the prefrontal cortex (PFC)
- The PFC normally exerts "top-down" control over the temporal cortex, parietal cortex, basal ganglia, amygdala, cerebellum, and corpus callosum to sustain attention, regulate impulse control, and facilitate working memory and cognitive flexibility
- PFC catecholamine dysfunction compromises these functions, producing the clinical manifestations of ADHD
Neuroimaging findings include reduced volume and activity in frontal-striatal circuits. Genetic studies consistently show heritability estimates of ~70–80%.
Evaluation & Diagnosis
- Clinical assessment — comprehensive history, behavioral observation; structured interviews such as the DIVA-5 (Diagnostic Interview for ADHD in Adults) for adults
- Rating scales — Vanderbilt Diagnostic Rating Scale (pediatrics), ASRS v1.1 (adult screening); input from parents, teachers, or other informants strongly recommended
- Neuropsychological/psychological testing — not required for diagnosis but useful when academic or developmental co-concerns exist
- Lab/imaging — generally not required if medical history is unremarkable
- qEEG — theta/beta ratio (TBR) is not a reliable diagnostic marker, but may have some prognostic value for stimulant and neurofeedback treatment response
Key differential diagnoses: Conduct disorder, oppositional defiant disorder (ODD), anxiety, depression, learning disorders. Adverse childhood events (ACEs) and trauma can also produce an ADHD-like presentation.
Epidemiology
- Prevalence (ages 2–17): 9.4% in the US (National Survey of Children's Health)
- Boys are more likely and earlier to be diagnosed than girls
- Girls more frequently present with the inattentive subtype and are often underdiagnosed
- Most affected children continue to meet diagnostic criteria through adolescence
Comorbidities are common in adults with untreated ADHD:
- ~5× increased risk for anxiety disorders
- ~4.5× increased risk for major depression
- ~8.7× increased risk for bipolar disorder
- ~4.6× increased risk for substance use disorders
Treatment
Treatment is most effective when pharmacologic and behavioral approaches are combined.
Non-Pharmacologic
- Behavioral therapy — first-line in preschool-age children (4–5 years); recommended as adjunct at all ages
- Parent training, classroom accommodations, organizational skills coaching
- Psychosocial treatment is described as "a critical part of care" regardless of age
Pharmacologic — Stimulants (First-Line)
Stimulants are the first-line pharmacotherapy, supported by multiple RCTs and meta-analyses. 65–75% of stimulant-treated youth respond, with similar rates for methylphenidate and amphetamine preparations.
Two main classes:
| Class | Examples |
|---|---|
| Methylphenidate (MPH) | Ritalin, Concerta, Focalin XR, Daytrana patch, Jornay PM |
| Amphetamines (AMPH) | Adderall XR, Vyvanse (lisdexamfetamine), Dexedrine |
Key principles:
- Extended-release (ER/MR) formulations are preferred over immediate-release — better adherence, sustained coverage, lower abuse/diversion liability
- "Booster" afternoon IR doses are sometimes needed with ER preparations
- Adequate MPH trial: >0.8 mg/kg/day; adequate amphetamine trial: ~0.5 mg/kg/day
- In adults, lisdexamfetamine is often first-choice, followed by methylphenidate; lisdexamfetamine also shows benefit in comorbid amphetamine/methamphetamine use disorders
Mechanism: Enhancement of dopaminergic and noradrenergic neurotransmission in the PFC.
Common side effects: Appetite suppression, abdominal pain, headaches, palpitations, sleep disturbance, potential growth effects with long-term use in children.
Cardiovascular note (important): Before initiating stimulants, screen for cardiac symptoms, Wolff-Parkinson-White syndrome, family history of sudden death, hypertrophic cardiomyopathy, and long QT syndrome. A 2024 population study found an increased (dose-related) risk of cardiovascular disease with stimulants — regular cardiovascular monitoring is recommended throughout treatment.
Pharmacologic — Non-Stimulants (Second-Line)
| Drug | Class | Notes |
|---|---|---|
| Atomoxetine | Selective NE reuptake inhibitor | Preferred when stimulants are contraindicated, misuse is a concern, or comorbid anxiety; slower onset (~4–6 weeks) |
| Viloxazine ER | NE reuptake inhibitor | FDA-approved for children/adolescents |
| Guanfacine ER | α2A-adrenergic agonist | Effective as monotherapy; also used for tics/aggression |
| Clonidine ER | α2-adrenergic agonist | Multiple RCTs support use in children/adolescents |
Devices
- Trigeminal nerve stimulation (e.g., Monarch eTNS) — FDA-cleared for children 7–12 as non-pharmacologic option
- Neurofeedback — meta-analyses suggest more sustained effects vs. non-active controls at ≥6 months post-treatment
Special Populations
Children (preschool, 4–5 years): Behavioral therapy alone is recommended before considering medication.
Adults: Adult diagnosis is valid; lisdexamfetamine or MPH ER is first-line. Annual medication review is recommended. Stimulants may worsen co-occurring bipolar disorder or psychosis — screen carefully.
Pregnancy: ADHD medications require careful risk-benefit assessment; see specific prescribing guidelines for management.
Prognosis & Long-Term Considerations
- Symptoms persist into adulthood in ~50% of those diagnosed in childhood
- Untreated ADHD is associated with car accidents, substance use in adolescents, job instability, and relationship difficulties in adults
- Long-term (>52 weeks) RCT data on outcomes is limited — assumptions about long-term efficacy should be made with caution
- Annual stimulant "holidays" or dose reductions should be considered to assess ongoing need and minimize adverse effects
Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; The Maudsley® Prescribing Guidelines in Psychiatry, 15th ed.; The Harriet Lane Handbook, 23rd ed.; Frontiers in Psychology 2025 (ADHD assessment review)
But what signs or history of the patient should be there
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
DSM-5 ADHD diagnostic criteria full symptom list inattention hyperactivity impulsivity signs history
Reading File
Reading File
I now have the complete DSM-5 symptom lists and the contextual qualifiers. Here's a thorough, clinically organized answer:
ADHD: Signs, Symptoms & History to Elicit
What You Are Looking For Clinically
ADHD presents through two core symptom domains — inattention and hyperactivity/impulsivity. For a diagnosis, these must not just be present, but persistent, pervasive, and impairing across multiple settings.
Domain 1: Inattention Symptoms
(Need ≥6 in children up to age 16; ≥5 in adolescents ≥17 and adults, for at least 6 months)
| # | Symptom | What it looks like in real life |
|---|---|---|
| a | Fails to give close attention / makes careless mistakes | Misses details in schoolwork, sloppy errors in homework or work tasks |
| b | Difficulty sustaining attention | Drifts off during lectures, reading, or conversations |
| c | Doesn't seem to listen when spoken to directly | "Mind seems elsewhere" even without obvious distractions |
| d | Doesn't follow through on instructions | Starts chores or homework but leaves them unfinished; loses focus mid-task |
| e | Difficulty organizing tasks and activities | Can't sequence tasks, misses deadlines, poor time management, messy workspace |
| f | Avoids tasks requiring sustained mental effort | Reluctant to do homework, dislikes reading long documents |
| g | Loses things | Misplaces pencils, keys, wallets, glasses, phone, school materials |
| h | Easily distracted by extraneous stimuli | In adults: also distracted by unrelated thoughts ("mind wandering") |
| i | Forgetful in daily activities | Forgets chores, appointments, returning calls, paying bills |
Domain 2: Hyperactivity & Impulsivity Symptoms
(Need ≥6 in children up to age 16; ≥5 in adolescents ≥17 and adults, for at least 6 months)
| # | Symptom | What it looks like in real life |
|---|---|---|
| a | Fidgets or squirms | Taps hands/feet, can't sit still |
| b | Leaves seat | Gets up in class, during meals, or meetings when expected to stay seated |
| c | Runs about or climbs | Inappropriate running/climbing; in adolescents/adults may be subjective restlessness |
| d | Can't play or do leisure quietly | Always loud, disruptive during quiet activities |
| e | "On the go" / driven by a motor | Seems unable to rest; others describe them as difficult to keep up with |
| f | Talks excessively | Dominates conversations, rarely lets others finish |
| g | Blurts out answers | Calls out before a question is finished; completes other people's sentences |
| h | Difficulty waiting their turn | Struggles in queues, games, or group activities |
| i | Interrupts or intrudes | Butts into conversations or games; uses others' belongings without asking |
Key History Points to Actively Elicit
1. Onset & Duration
- Symptoms must have first appeared before age 12 — ask parents or caregivers about early childhood behavior
- Must have persisted ≥6 months continuously
2. Pervasiveness (Two or More Settings)
- Ask separately about home, school/work, social situations, and extracurricular activities
- Symptoms only at school → think situational stress or learning disorder
- Symptoms only at home → think family/environment issues
- True ADHD is present everywhere
3. Functional Impairment
- Academic failure or underachievement
- Job loss, frequent job changes
- Relationship difficulties, social rejection
- Low self-esteem
- Traffic accidents (especially in adolescents/adults)
4. Developmental & Early Childhood History
- Was the child described as "always on the go," "a handful," or "very active" as a toddler?
- School reports — teacher complaints about behavior, attention, or academic performance
- History of repeating grades, extra tutoring, or special education
5. Family History
- ADHD is highly heritable (~70–80%)
- Ask about parents or siblings diagnosed with ADHD, learning disabilities, or behavioral issues
6. Comorbid Conditions to Screen For
These frequently co-occur and must be identified:
| Comorbidity | Why it matters |
|---|---|
| Anxiety disorder | 5× higher risk; can mimic or worsen inattention |
| Depression / MDD | 4.5× higher risk; sadness/fatigue can impair concentration |
| Oppositional Defiant Disorder (ODD) | Very common in children; affects behavior management |
| Conduct disorder | More serious behavioral pattern |
| Learning disorders (dyslexia, dyscalculia) | Can co-occur and compound academic struggles |
| Bipolar disorder | 8.7× higher risk in adults — important to rule out before starting stimulants |
| Substance use disorder | 4.6× higher risk; stimulant diversion is a concern |
| Tic disorders / Tourette syndrome | Dopaminergic connection; affects medication choice |
| Sleep disorders | Can be primary or stimulant-induced |
7. Trauma & Adverse Childhood Events (ACEs)
- Trauma exposure can produce an ADHD-like presentation — ask about abuse, neglect, domestic violence, or major losses
- These patients need therapy referral, not necessarily stimulants
8. Medical & Cardiac History (Before Prescribing)
- Rule out: Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome, family history of sudden cardiac death
- Ask about: palpitations, chest pain, syncope on exertion
9. Adult-Specific History
- Academic history (college dropout, poor grades despite average or high intelligence)
- Employment instability, frequent job changes
- Relationship difficulties, multiple failed relationships
- History of "always being disorganized" since childhood
- Prior diagnosis in childhood, even if not officially documented
Signs on Examination
ADHD is primarily a history-based diagnosis — there are no specific physical examination findings. However, you may observe:
- Restlessness during the interview (unable to sit still, fidgeting)
- Distractibility (loses track of conversation, easily pulled by external stimuli)
- Impulsive speech (interrupts, answers before questions are finished)
- Disorganized thought or tangential responses
- Difficulty with tasks requiring sustained focus on formal cognitive/neuropsychological testing
- Elevated heart rate or blood pressure (if already on stimulants)
Threshold Reminder
| Age | Inattention symptoms needed | Hyperactivity/Impulsivity symptoms needed |
|---|---|---|
| Up to age 16 | ≥6 | ≥6 |
| Age 17+ / Adults | ≥5 | ≥5 |
Symptoms must not be better explained by another mental disorder (mood disorder, anxiety, psychosis, dissociative disorder, or personality disorder), and must not occur exclusively during the course of schizophrenia or another psychotic disorder.
Sources: DSM-5 criteria as cited in Conn's Current Therapy; Goldman's Cecil Medicine; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Harriet Lane Handbook, 23rd ed.
This is a shared conversation. Sign in to Orris to start your own chat.